Healthcare / BiotechnologyNasdaqGS
$29.13
+0.24 (+0.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.5M · quality 38.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.3%
↓Gross Margin
98.7%
↑Debt/Equity
1.15
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+214.7%
FCF CAGR
—
FCF margin
-3.8%
FCF / Net income
0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $400.0M · net income $-35.5M · FCF $-15.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $400.0M | $400.0M | $310.2M | $249.4M | $174.4M | $4.1M |
| Net Income | $-35.5M | $-35.5M | $-51.1M | $-55.3M | $-52.5M | $-180.0M |
| EBITDA | $-3.7M | $-3.7M | $-29.9M | $-51.6M | $-30.1M | $-167.0M |
| EPS | -0.71 | -0.71 | -1.02 | -1.13 | -1.09 | -4.24 |
| Gross Margin | 98.7% | 98.7% | 99.1% | 99.6% | 99.4% | — |
| Operating Margin | -11.3% | -11.3% | -22.7% | -23.9% | -29.7% | -4281.2% |
| Net Margin | -8.9% | -8.9% | -16.5% | -22.2% | -30.1% | -4414.6% |
| Balance Sheet | ||||||
| Debt/Equity | 1.15 | 1.15 | 1.20 | 0.23 | 0.24 | — |
| Current Ratio | 4.18 | 4.18 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-15.1M | $-15.1M | $20.9M | $-2.5M | $-51.4M | $-144.5M |
| Returns | ||||||
| ROE | -9.3% | -9.3% | -14.2% | -15.0% | -15.5% | -77.0% |
| Valuation | ||||||
| P/B | 3.85 | 3.85 | 4.14 | 8.82 | 7.37 | — |
| Growth & Yield | ||||||
| Revenue Growth | 29.0% | 29.0% | 24.4% | 43.1% | — | — |
| EPS Growth | 30.4% | 30.4% | 9.7% | -3.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.02 → -0.71
Residual
-20.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.